Celadon Pharmaceuticals PLC Appointment of CFO (8069E)
01 November 2022 - 6:00PM
UK Regulatory
TIDMCEL
RNS Number : 8069E
Celadon Pharmaceuticals PLC
01 November 2022
Celadon Pharmaceuticals Plc
("Celadon", the "Company" or the "Group")
Appointment of CFO
London, 1 November 2022 - Celadon Pharmaceuticals Plc (AIM:
CEL), a UK-based pharmaceutical company focused on the research,
cultivation, manufacturing, and sale of breakthrough cannabis-based
medicines, today announces the appointment of Jonathan Turner as
Chief Financial Officer of the Group. Jonathan will start a phased
transition into his role from November 2022 and will join the
Company on a full time basis from February 2023. He will be
appointed to the Board at that time.
Jonathan succeeds Katie Long who is returning to her role within
Tessera Investment Management Limited ("Tessera"), having
established and led Celadon's finance function over the previous
year and during the Company's AIM IPO. Katie will continue to
provide support to the Company through to the commencement of
Jonathan's appointment on a full time basis, and will step down
from the Board at that time.
Jonathan joins from FTSE250 listed Oxford Instruments plc (LSE:
OXIG), where he has been Group Director of Accounting, Tax and
Treasury since September 2020, and a Divisional Finance Director
for the three years before that. During this time, he has worked
closely with the Oxford Instruments plc's CFO and has been
responsible for internal and external financial reporting, and
developing and maintaining financial and operational systems.
Prior to this, Jonathan was Group Company Secretary and Head of
Tax and Treasury for FTSE listed Synergy Health plc ("Synergy") and
Finance Director for NYSE listed STERIS plc, following its
acquisition of Synergy. Jonathan is a Chartered Accountant and
Associate Member of the Association of Corporate Treasurers and was
previously a Senior Manager at EY, where he worked from 2003 until
2010, and originally qualified at Smith & Williamson.
James Short, CEO of Celadon, said:
"We are delighted to welcome Jonathan to the Group. His
extensive experience operating within technology, manufacturing and
scientific research industries will be important as Celadon
continues to advance its position as a leading UK provider of
breakthrough cannabis-based medicines.
"The Board would like to take this opportunity to thank Katie
for her invaluable contribution since joining Celadon in February
2021, which has been a pivotal time in the Company's development.
We wish her well on her return to Tessera."
The following information is disclosed pursuant to Schedule Two
paragraph (g) of the AIM Rules for Companies. Jonathan Paul Turner,
aged 44 years, has been a director of the following companies
during the five years preceding the date of this announcement:
Current directorships Past Directorships
Oxford Instruments Overseas Oxford Instruments Nanotechnology
Holdings 2008 (since August Tools Limited (April 2018
2020) - August 2020)
Oxford Instruments Nanotechnology Oxford Instruments Industrial
Tools Holdings Limited Products Limited (April
(since August 2020) 2018 - July 2020)
Oxford Instruments Industrial
Products Holdings Limited
(since August 2020)
Oxford Instruments AFM
Limited (since August
2020)
Oxford Instruments Molecular
Biotools Limited (since
August 2020)
Oxford Instruments UK
2013 Limited (since August
2020)
Oxford Instruments Holdings
Europe Limited (August
2020)
Oxford Instruments Overseas
Holdings Limited (since
August 2020)
Oxford Instruments Funding
Limited (since August
2020)
Mr Turner is expected to resign from the above directorships
ahead of his formal appointment as a director of the Company.
Mr Turner was Director of, and Company Secretary to Shiloh
Properties Limited between July 2014 and December 2016. The Company
was dissolved via a Compulsory Strike Off in January 2022 following
a restoration by court order from a previous voluntary wind-up of
the Company. Mr Turner is not aware of any shortfall to
creditors.
The Company confirms that there is no further information to be
disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the
AIM Rules for Companies.
Enquiries:
Celadon Pharmaceuticals Plc
James Short Via Powerscourt
Arthur Wakeley
Canaccord Genuity Limited (Nominated
Adviser and Broker)
Bobbie Hilliam / Andrew Potts / Patrick
Dolaghan +44 (0)20 7523 8000
Powerscourt Group
Sarah MacLeod / Nick Johnson / Sam Austrums +44 (0)20 7250 1446
/ celadon@powerscourt-group.com
Ibrahim Khalil
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company
focused on the research, cultivation, manufacturing, and sale of
breakthrough cannabis-based medicines. Its primary focus is on
improving quality of life for chronic pain sufferers, as well as
exploring the potential of cannabis-based medicines for other
conditions such as autism. Its 100,000 sq. ft UK facility comprises
a laboratory designed to meet GMP standards, and capacity for a
large indoor hydroponic growing facility that has received a Home
Office Licence to legally grow high-THC medicinal cannabis for the
purpose of producing test batches of cannabis oil to support its
application to the MHRA. The Company's subsidiary, LVL, owns a MHRA
conditionally-approved cannabis trial using cannabis based
medicinal products to treat chronic pain in the UK.
For further information please visit our website
www.celadonpharma.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAFZMFGNMRGZZM
(END) Dow Jones Newswires
November 01, 2022 03:00 ET (07:00 GMT)
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Apr 2024 to May 2024
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From May 2023 to May 2024